as of 11-19-2026 3:59pm EST
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
| Founded: | 1994 | Country: | United States |
| Employees: | 6 | City: | CAMBRIDGE |
| Market Cap: | 6.4M | IPO Year: | 2000 |
| Target Price: | N/A | AVG Volume (30 days): | 27.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.17 | EPS Growth: | -90.34 |
| 52 Week Low/High: | $1.17 - $795.00 | Next Earning Date: | 11-13-2026 |
| Revenue: | $39,914,675 | Revenue Growth: | -7.17% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.65 | Index: | N/A |
| Free Cash Flow: | -8146723.0 | FCF Growth: | N/A |
SEC 8-K filings with transcript text
Nov 13, 2026 · 100% conf.
1D
-4.02%
$1.46
Act: -4.28%
5D
-9.55%
$1.37
20D
-13.37%
$1.32
2 ex99-1.htm
Exhibit 99.1
Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Development Highlights:
●Advancing final IND-enabling activities to support the planned EB-003 IND application
●Completed IND-enabling absorption and metabolic studies with favorable findings supporting EB-003’s potential for reduced drug-drug interactions
●Reported preclinical qEEG results demonstrating brain penetration and activity distinct from DMT, supporting evaluation as a potential biomarker
●Reported in vitro mechanistic studies, supporting EB-003’s predicted non-hallucinogenic profile
Corporate and Business Development Highlights:
●Secured U.S. patent allowance for next-generation, non-hallucinogenic mescaline derivatives in EVM401 Series
●Supported the FDA release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics.
Mass., November 13, 2026 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a comprehensive business update.
CEO Commentary:
“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate,” said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric. “The data generated during the quarter and in recent weeks strengthen the foundation for this next stage and reinforce the opportunity to develop EB-003 as a differentiated treatment for psychiatric and neurological disorders.”
Dr. Tucker continued: “Recently completed studies of EB-003 have provided important, complementary evidence demonstrating its differentiated profile and potential advantages. Independent assay platforms, including GloSensor™ and BRET, have consistently supported its predicted non-hallucinogenic profile, while our completed in vitro ADMET studies indicate favorable absorption and metabolic properties and a reduced potential for drug-drug interactions. The qEEG study adds functional evidence of brain penetration and a pattern of brain activity distinct from dimethyltryptamine (DMT). It also supports evaluating qEEG in human studies to connect drug exposure with brain activity and help guide dose selection.”
“As the FDA continues to define the regulatory framework for psychedelic-inspired therapies, we believe EB-003’s design has the potential to offer advantages in clinical development while supporting broader patient access and potential commercial adoption,” Dr. Tucker concluded. “By seeking to harness the therapeutic potential of neuroplasticity without requiring a hallucinogenic experience, our approach could support a simpler outpatient treatment model. The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”
Corporate, Product and Business Development Highlights:
Development:
●Reported a preclinical qEEG study demonstrating functional evidence of central nervous system penetration and a brain activity profile distinct from the classic psychedelic DMT
○Results support use of qEEG as a potential pharmacodynamic biomarker in first-in-human development
●Announced positive results from recently completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies for EB-003
●Reported findings from a highly sensitive GloSensor™ cAMP assay that provided additional evidence supporting EB-003’s predicted non-hallucinogenic profile
●Supported the release of finalized guidance from FDA for clinical investigations of psychedelic and psychedelic-inspired therapeutics
Intellectual Property:
●Secured New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Net loss attributable to stockholders was $2.5 million for the third quarter ended September 30, 2026, including $0.2 million in net non-cash expense, with a basic and diluted loss per share of $0.57, as compared to a net loss attributable to stockholders of $3.4 million, including $0.1 million in net non-cash expense, with a basic and diluted loss per share of $10.81 for the quarter ended September 30, 2025. The net loss attributable to stockholders for the quarter ended September 30, 2025 also included a $1.5 million deemed dividend on the inducement of warrants, which did not recur in the quarter ended September 30, 2026. The Company had cash-on-hand of $5.6 million as of September 30, 2026.
About
Aug 14, 2026 · 100% conf.
1D
-4.00%
$1.47
Act: -3.58%
5D
-9.77%
$1.39
20D
-8.57%
$1.40
Transcript text not available. View on SEC.gov →
May 15, 2026 · 100% conf.
1D
+1.43%
$2.27
Act: -3.80%
5D
+7.43%
$2.40
Act: -1.11%
20D
+40.01%
$3.13
2 ex99-1.htm
Exhibit 99.1
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Product Development Highlights:
●Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial
●Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects
Corporate and Business Development Highlights:
●Strengthened intellectual property portfolio with new patent issuances and allowances across EVM301 and EVM401 series
●Announced the withdrawal by AbbVie, Inc. of the Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276, which appears relevant to the bretisilocin molecule (GM-2505) acquired by AbbVie, Inc.
●Presented at and Participated in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
Mass., May 15, 2026 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a comprehensive business update.
CEO Commentary:
“Our progress in the first quarter of 2026 reflects continued execution against our core mission of developing therapeutics capable of addressing the significant unmet need in mental health,” said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences. “We remain laser focused on advancing EB-003, Enveric’s lead drug candidate in developlment, toward an IND submission and first-in-human clinical trials.”
Dr. Tucker continued: “What differentiates Enveric is our commitment to harnessing the therapeutic potential of psychedelic-inspired mechanisms while designing our candidates to eliminate the hallucinogenic effects that limit scalability, safety, and broad patient access. Our growing body of preclinical data continue to support EB-003’s ability to promote neuroplasticity through selective receptor engagement, reinforcing our confidence in its potential to deliver rapid and durable antidepressant and anxiolytic effects.”
“Since the end of the first quarter, the broader policy environment appears to be increasingly supportive of innovation in mental health. Recent actions, including an Executive Order issued under President Donald Trump emphasizing the importance of advancing novel treatments for mental health conditions, underscore growing recognition of the therapeutic promise of psychedelic-inspired compounds. We believe the future of this field will be defined by non-hallucinogenic neuroplastogens like EB-003, which is designed to deliver the benefits of these pathways while avoiding the limitations associated with traditional psychedelic therapies.”
Dr. Tucker continued: “In parallel, we continue to view our intellectual property estate as a foundational driver of long-term value creation. The recent withdrawal of the Post-Grant Review petition by AbbVie further underscores the strength, breadth and strategic relevance of our patent portfolio. We believe our expanding IP position not only protects our innovations but also enhances our ability to create future partnering and monetization opportunities.”
Dr. Tucker concluded: “With IND-enabling activities underway and a strong intellectual property position, we believe Enveric is well positioned to generate meaningful value for stockholders as we transition toward the clinical phase of drug development.”
Corporate, Product and Business Development Highlights:
Development:
●Reported EB-003 BRET receptor engagement assay data, demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways that have been linked in peer-reviewed studies to antidepressant and anxiolytic effects
●Subsequent to the end of the first quarter, highlighted positive results for EB-003 indicating a rapid reduction in conditioned fear response in a validated preclinical model of PTSD, supporting continued development for patient population with significant unmet need
Intellectual Property:
●Announced the withdrawal of the Post-Grant Review (PGR) petition, which had been filed by Gilgamesh Pharmaceuticals, pertaining to patents that appear relevant to the bretisilocin (GM-2505) molecule, which was acquired by AbbVie, Inc. in $1.2 billion deal
●Added depth to EVM301 intellectual property portfolio for non-hallucinogenic treatment of neuropsychiatric conditions, enhancing the patent claim coverage of Enveric’s N-heterocycle substituted tryptamine derivative molecules
●Registered five of the Company’s trademarks, including its house marks, Enveric and Enveric Biosciences, with the Canadian
See how ENVB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ENVB Enveric Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.